PHARMACOKINETICS OF CEFODIZIME IN ELDERLY PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

被引:6
|
作者
VEYSSIER, P
DEVILLERS, A
DOMART, Y
FOURTILLAN, JB
BRYSKIER, A
PROCYK, T
机构
[1] CHU POITIERS,F-86021 POITIERS,FRANCE
[2] CTR HOSP V DUPOUY,ARGENTEUIL,FRANCE
关键词
D O I
10.1093/jac/26.suppl_C.77
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In young adults, the elimination half-life of cefodizime is 3.5—4 h. A pharmacokinetic study was performed in eight patients, aged 63 to 85 years, divided into two groups with the following creatinine clearances (group I: ≥ 50 ml/min and group II: < 30 ml/min). Cefodizime was administered as a 1.0-g iv bolus. In group I, pharmacokinetic parameters did not differ from those observed in young healthy volunteers in a previous study. In group II, the half-life was increased (3.42–7.41 h). There is a linear correlation between the creatinine clearance and total clearance. The daily dose given needs to be based not on the age of the patient but on the degree of renal impairment. In elderly patients with severe renal impairment, the daily dose should be reduced if the creatinine clearance falls below 30 ml/min. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF FLUPIRTINE IN ELDERLY VOLUNTEERS AND IN PATIENTS WITH MODERATE RENAL IMPAIRMENT
    ABRAMS, SML
    BAKER, LRI
    CROME, P
    WHITE, AST
    JOHNSTON, A
    ANKIER, SI
    WARRINGTON, SJ
    TURNER, P
    NIEBCH, G
    POSTGRADUATE MEDICAL JOURNAL, 1988, 64 (751) : 361 - 363
  • [2] Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
    Min, K. Chris
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Wrishko, Rebecca E.
    Hanley, William D.
    Wolford, Dennis G.
    de Haes, Joanna Udo
    Reitmann, Christina
    Gutstein, David E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 746 - 752
  • [3] Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment
    Ramesh Boinpally
    Harry Alcorn
    Marijke H. Adams
    James Longstreth
    John Edwards
    Clinical Drug Investigation, 2013, 33 : 199 - 206
  • [4] Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment
    Boinpally, Ramesh
    Alcorn, Harry
    Adams, Marijke H.
    Longstreth, James
    Edwards, John
    CLINICAL DRUG INVESTIGATION, 2013, 33 (03) : 199 - 206
  • [5] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S87 - S88
  • [6] Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
    Kumar, Ashish
    Hariri, Ali
    Lee, Yunjung
    Lee, Minhyung
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2213 - 2215
  • [7] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [8] PHARMACOKINETICS OF FLECAINIDE ACETATE IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
    WILLIAMS, AJ
    MCQUINN, RL
    WALLS, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) : 449 - 455
  • [9] Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
    Anne-Kristina Mercier
    Mikael Sunnåker
    Sebastian Ueckert
    Tadeusz Pawlik
    Emilia Henricson
    Oleksandr Molodetskyi
    Gordon C. Law
    Victoria E. R. Parker
    Jan Oscarsson
    Clinical Pharmacokinetics, 2023, 62 : 1713 - 1724
  • [10] Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
    Mercier, Anne-Kristina
    Sunnaker, Mikael
    Ueckert, Sebastian
    Pawlik, Tadeusz
    Henricson, Emilia
    Molodetskyi, Oleksandr
    Law, Gordon
    Parker, Victoria
    Oscarsson, Jan
    CLINICAL PHARMACOKINETICS, 2023, 62 (12) : 1713 - 1724